Royalty Pharma plc

RPRX

GB00BMVP7Y09

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 04:00:00 2025-07-09 pm EDT			5-day change	1st Jan Change
35.93 ^USD	+1.18%		-1.37%	+39.93%

Jun. 30	Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Index	CI
Jun. 30	Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Defensive Index	CI

Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 05/08/2025 at 07:32

Royalty Pharma plc reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported revenue was USD 568.25 million compared to USD 568 million a year ago. Revenue was USD 568.25 million compared to USD 567.98 million a year ago.

Net income was USD 238.35 million compared to USD 5 million a year ago. Net income was USD 238.35 million compared to USD 4.78 million a year ago. Basic earnings per share from continuing operations was USD 0.55 compared to USD 0.01 a year ago.

Diluted earnings per share from continuing operations was USD 0.55 compared to USD 0.01 a year ago.

Latest news about Royalty Pharma plc

Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Index	Jun. 30	CI
Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Defensive Index	Jun. 30	CI
Royalty Pharma and Revolution Medicines Enter into Funding Agreements for Up to $2 Billion	Jun. 24	CI
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug	Jun. 24	RE
Revolution Medicines Signs $2 Billion Funding Deal With Royalty Pharma	Jun. 24	MT
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug	Jun. 24	RE
Royalty Pharma plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 02:00 PM	Jun. 10
Theravance Shares Rise Premarket on Sale of Trelegy Royalties	Jun. 02	DJ
Theravance to Sell Remaining Royalty Interest in Trelegy Ellipta Sales to GSK for $225 Million	Jun. 02	MT
Royalty Pharma plc Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 04:05 PM	May. 20
Royalty Pharma Closes Acquisition of External Manager	May. 16	MT
Royalty Pharma Completes The Acquisition Of Its External Manager	May. 16	RE
Royalty Pharma plc Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 02:20 PM	May. 14
Royalty Pharma Shareholders Approve External Manager Acquisition	May. 12	MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025.	May. 08	CI
Royalty Pharma plc, Q1 2025 Earnings Call, May 08, 2025	May. 08
Royalty Pharma Q1 Net Income Rises, Revenue Unchanged	May. 08	MT
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 08	CI
Earnings Flash (RPRX) Royalty Pharma Posts Q1 Revenue $568M	May. 08	MT
BofA Adjusts Price Target on Royalty Pharma to $42 From $41	Apr. 21	MT
Royalty Pharma plc Appoints Vlad Coric, M.D. to Its Board of Directors	Apr. 08	CI
Royalty Pharma Announces Upcoming Investor Day	Mar. 27	RE
Royalty Pharma plc Presents at TD Cowen 45th Annual Healthcare Conference, Mar-04-2025 02:30 PM	Mar. 04
Biogen Expects Decline in 2025 Revenue, Reports Fourth-Quarter Beat	Feb. 12	MT
Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D	Feb. 12	MT

Chart Royalty Pharma plc

Duration

Period

RPRX: Dynamic Chart

Company Profile

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâs Trikafta, GSKâs Trelegy, Rocheâs Evrysdi, Johnson & Johnsonâs Tremfya, Biogenâs Tysabri and Spinraza, AbbVie and Johnson & Johnsonâs Imbruvica, Astellas and Pfizerâs Xtandi, Novartisâ Promacta, Pfizerâs Nurtec ODT and Gileadâs Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 05 - Q2 2025 Earnings Release (Projected)

More about the company